Share on StockTwits

EXACT Sciences (NASDAQ:EXAS)‘s stock had its “buy” rating reaffirmed by analysts at Canaccord Genuity in a research report issued to clients and investors on Tuesday. They currently have a $20.00 price target on the stock, up from their previous price target of $19.00. Canaccord Genuity’s price target would indicate a potential upside of 17.03% from the stock’s previous close.

Shares of EXACT Sciences (NASDAQ:EXAS) traded up 6.96% on Tuesday, hitting $18.28. 7,426,546 shares of the company’s stock traded hands. EXACT Sciences has a 1-year low of $9.53 and a 1-year high of $17.74. The stock’s 50-day moving average is $16.42 and its 200-day moving average is $14.19. The company’s market cap is $1.516 billion.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Tuesday, July 22nd. The company reported ($0.24) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.25) by $0.01. During the same quarter last year, the company posted ($0.19) earnings per share. On average, analysts predict that EXACT Sciences will post $-1.14 earnings per share for the current fiscal year.

A number of other firms have also recently commented on EXAS. Analysts at Benchmark Co. upgraded shares of EXACT Sciences to a “buy” rating in a research note on Tuesday. Separately, analysts at Jefferies Group raised their price target on shares of EXACT Sciences from $18.00 to $20.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. Finally, analysts at Maxim Group reiterated a “sell” rating on shares of EXACT Sciences in a research note on Wednesday, July 23rd. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.50.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.